Author: The Bull

The Bull
The Bull

feedback or questions?

Include your name, the article headline and your message.

EMAIL THE AUTHOR

FOLLOW ELSEWHERE

Recent and archived work by The Bull for The Bull:
ECB rate meeting

ASX200 Up Marginally Monday, What Will Central Banks Bring?

The local equities market was witness to a barely noticeable uptick as the ASX 200 closed 5.5 points higher on Monday, marking a modest rise of 0.07% from the previous week’s downturn. However, beneath this seemingly flat surface, sectors like base metals, lithium, and uranium stock demonstrated more exuberant activity as their prices experienced rallies…

AUB Group (ASX:AUB) Shares Drop On The Day, But Huge Gains On The Year

Investors in AUB Group Shares (ASX:AUB), a prominent player in the insurance broking and underwriting sector in Australia and New Zealand, are basking in the success of a 7.81% increase year to date. This figure highlights the substantial gains shareholders have enjoyed, far exceeding the pain of a total loss one might fear in stock…

Is it Too Late to Buy Sigma Healthcare

Proteomics International’s (ASX:PIQ) Delays the Launch of Kidney Disease Test in US

Proteomics International Laboratories (ASX:PIQ), a pioneer in the field of biomarker discovery and application, has suffered a stock price plummet following the announcement of a delay in the US market launch of its ground-breaking kidney disease predictive test. News of the setback saw the company’s shares tumble nearly 23%, wiping out recent gains as investors…

ASX This Week (W/C 18th March) – Earnings Thin On The Ground

As we get ready for a new week in the Aussie stock market, a little reflection on the last week is at least earned. With the ASX200 having seen a 2.25% drop and the XAO (All Ords) down 0.63%, we may be feeling a little bruised but it is always worth taking a longer view…

(ASX:MPL) Medibank Private Shares Up Strongly In March, Current Price Targets Close

In recent months, Medibank Private Limited stock price (ASX:MPL) has witnessed a solid surge, with shares ascending by 7.5% YTD. This rally has encapsulated investor confidence and sparked a wave of optimistic discourse among market analysts observing the health insurer. In comparison, the ASX200 has risen by 0.56% over the same period, so this is…

A resurgent dollar

Aussie Dollar Rallies Against USD Amid Uncertain Print

The Australian dollar has been experiencing upward momentum over the past month, riding the coattails of rallying gold prices against the USD. AUDUSD has strengthened just shy of 0.8% over the past month, from a longer growth period of 2.2% over the preceding six. This represents a marked turnaround from the past few years where…

Apple (NASDAQ:AAPL) Poised to Propel Forward in AI – Shares Up More Than 1% In US AM

In an industry shift that signals Apple Inc.’s (NASDAQ:AAPL) intensified focus on artificial intelligence, the tech behemoth is on the brink of acquiring Brighter AI, a privately held startup that specialises in anonymizing private data within images. This tactical move aligns with Apple’s broader strategy to embed cutting-edge AI technology into its suite of products,…

Copper Stocks Shine While ASX 200 Dips Amid Macquarie’s Bank Downgrades

In today’s financial exchange, the ASX 200 index witnessed a minor decline, closing 15.8 points lower, representing a 0.20% dip in its overall value. Despite this modest drop, specific sectors and commodities contributed to a dynamic day in the markets. The limelight was undoubtedly taken by copper stocks, which experienced a prosperous ride due to…

Australia and New Zealand Banking Group (ASX:ANZ) Displaying a High Yield and Potential for Growth

In the bustling landscape of the ASX, the Australia and New Zealand Banking Group Limited (ASX:ANZ) stands out as a beacon for income-focused investors. Currently flaunting a dividend yield of 6.02%, ANZ has surpassed the banking sector’s average yield of 2.11%, delineating its commitment to shareholder returns. As the financial year marches on, ANZ’s performance…

Neurotech International (ASX:NTI) Extends NTI164 Rett Syndrome Clinical Trial to a Year

The biopharmaceutical development company Neurotech International (ASX:NTI) is extending the beacon of hope for those affected by Rett Syndrome with a significant expansion of its Phase I/II clinical trial. The investigation into the NTI164 drug formulation, derived from a specialized cannabis strain, will now continue for 52 weeks, marking an ambitious step in the hunt…